65,437 trials
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants
Intra-abdominal Infections
Primary: Clinical Response: Response Rate (Data Review Committee Assessment) — 96.6; 96.7 percentage of participants
Idiopathic Parkinson's Disease
Primary: Mean Score of the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication — 1.32 units on a scale
Pituitary Tumors
Primary: Change in Mean Survey Response From Baseline to 90 Days Post Surgery — 17.3; 13.5 units on a scale — p=0.001
Tobacco Dependence
Primary: Number of Nicotine Cigarette Choices Taken During the Cigarette Choice Procedure. — 18.5; 16.2 Number of Nicotine Cigarette Puffs Taken
Healthy
Primary: Imaging Quality Score — 2.1; 2.1; 2.3 Units on a visualization score scale
Anesthesia; Adverse Effect, Spinal and Epidural, Headache · Complications; Anesthesia, Spinal and Epidural, in Pregnancy
Primary: Postdural Puncture Headache in Patients Receiving Spinal Anesthesia for Cesarean Section — 14; 10 participants
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or…
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 68.7; 40.0 Percentage of participants
Hematologic Malignancies
Primary: Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality — 1 participants
Precocious · Leuprolide Acetate · Luteinizing Hormone (LH)
Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone — 96.9; 100.0; 93.8; 100.0 percentage of participants
Atherosclerosis · Stroke · Carotid Stenosis
Primary: Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years…
Lung Neoplasms · Carcinoma · Cancer of the Lung
Primary: Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study…
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001